Fortunately, tremendous progress has been made in deciphering the molecular pathogenesis of AML, enabling the development of target drugs, such as the introduction of small-molecule inhibitors of FLT3, IDH1/IDH2, and BCL-2. Here, IDH1 is linked to acute myeloid leukemia.